Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden. © 2018 Merck Sharp & Dohme Corp., and The Authors

• Fecha de publicación: 2018
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/18762
• Acceso en línea: https://doi.org/10.1016/j.pvr.2017.12.004; http://repository.urosario.edu.co/handle/10336/18762
• Palabra clave: 9Vhpv; Cervical Cancer; Human Papillomavirus; Persistent Infection; Vaccine; Virus Antibody; Virus Dna; Wart Virus Vaccine; Adolescent; Adult; Adverse Event; Antibody Blood Level; Antibody Response; Article; Blood Analysis; Child; Controlled Study; Disease Association; Dizziness; Double Blind Procedure; Drug Efficacy; Drug Fatality; Drug Safety; Female; Fever; Gynecological Examination; Headache; Hispanic; Human; Human Papillomavirus Type 31; Human Papillomavirus Type 33; Human Papillomavirus Type 45; Human Papillomavirus Type 52; Human Papillomavirus Type 58; Injection Site Erythema; Injection Site Pain; Injection Site Pruritus; Injection Site Swelling; Major Clinical Study; Male; Nausea; Papillomavirus Infection; Priority Journal; Randomized Controlled Trial; Seroconversion; Treatment Outcome; Uterine Cervix Cytology; Uterine Cervix Dysplasia; Vaccination; Vaccine Immunogenicity; Vagina Disease; Vagina Smear; Vomiting; Vulva Disease; Papiloma; Neoplasias del cuello uterino; Vacuna contra papilomavirus
• License: Abierto (Texto Completo)